Omeros Corporation

Peter Kurt Nollert Von Specht

Jennifer Lynn Gage

Thomas L Little, Jr

Neil S Cutshall

Markus Metz

Jennifer Tsoung

Sara Rebecca Goldstein

Do Yeon Kwon

Santosh Kumar Keshipeddy

Robert Huerta Lemus

Jeremiah H Nguyen

Michael Cicirelli

Sudheer Babu Vaddela

Juhienah Khalaf

Franz A Gruswitz

Loren Michael Price

Thomas Dudler

Munehisa Yabuki

Sadam Yaseen

Melinda Davis

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

MASP-2 inhibitors and methods of use

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

Isolated monoclonal antibodies and antigen-binding fragments thereof are provided that specifically bind to an epitope within the serine protease domain of human MASP-2. In some embodiments, the antibodies or antigen-binding fragments thereof inhibit lectin pathway complement activation. Also provided are polynucleotides encoding the disclosed monoclonal antibodies or antigen-binding fragments thereof, and cloning vectors or expression cassettes comprising such polynucleotides. Further provided are methods of inhibiting lectin pathway complement activation and methods of treating lectin pathway diseases and disorders.

Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof

Growing community of inventors

Bainbridge Island, WA, United States of America

Peter Kurt Nollert Von Specht